Gilead ups its bet on Arcellx and BCMA
The new deal comes as Carvykti manufacturing problems continue and 2seventy dials down Abecma expectations.
The new deal comes as Carvykti manufacturing problems continue and 2seventy dials down Abecma expectations.
Novartis and Gracell place further bets on shortened production times, with Bristol waiting in the wings.
The once-hyped group’s most advanced hope is an allogeneic CD19 Car-T, where competition is fierce.
The big pharma group had two anti-BCMA assets to choose from, and yesterday gave Harpoon the bad news.
Less than two months after a patient death CART-ddBCMA’s pivotal multiple myeloma trial is cleared to restart.